Aerovate Therapeutics, Inc.

NasdaqGM:AVTE 주식 보고서

시가총액: US$48.7m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aerovate Therapeutics 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Tim Noyes

최고 경영자

US$3.1m

총 보상

CEO 급여 비율19.1%
CEO 임기3.2yrs
CEO 소유권n/a
경영진 평균 재임 기간2.7yrs
이사회 평균 재임 기간3.3yrs

최근 관리 업데이트

Recent updates

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Jun 11

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

May 24
Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Feb 09
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Oct 17
We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Jul 04
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Feb 28
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Jan 06
A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Oct 14
Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Jan 22
We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Sep 30
Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

CEO 보상 분석

Tim Noyes 의 보수는 Aerovate Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$82m

Dec 31 2023US$3mUS$586k

-US$76m

Sep 30 2023n/an/a

-US$70m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$57m

Dec 31 2022US$704kUS$563k

-US$52m

Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$5mUS$437k

-US$23m

보상 대 시장: Tim 의 총 보상 ($USD 3.07M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Tim 의 보상이 증가했습니다.


CEO

Tim Noyes (62 yo)

3.2yrs

테뉴어

US$3,070,657

보상

Mr. Timothy P. Noyes, MBA, also known as Tim, has been the Chief Executive Officer of Aerovate Therapeutics, Inc. since May 2021 and has been its Director since April 2021. Mr. Noyes serves as Venture Part...


리더십 팀

이름위치테뉴어보상소유권
Timothy Noyes
CEO & Director3.2yrsUS$3.07m데이터 없음
George Eldridge
CFO & Treasurer3.3yrsUS$2.13m0.017%
$ 8.5k
Timothy Pigot
Chief Commercial Officer3.1yrsUS$2.45m0.011%
$ 5.5k
Benjamin Dake
Founder6yrsUS$2.88m0.0045%
$ 2.2k
Marinus Verwijs
Chief Technical Officer1.1yrsUS$1.32m데이터 없음
Ralph Niven
Chief Scientific Officer1.9yrsUS$433.20k0.0056%
$ 2.7k
Hunter Gillies
Chief Medical Officer4.2yrsUS$1.63m0.019%
$ 9.5k
Donna Dea
Head of Regulatory Affairs3.8yrs데이터 없음데이터 없음
Susan Fischer
Executive Vice President of Development Operations2.3yrs데이터 없음데이터 없음
Stephen Yu
Senior Vice President of Quality1.9yrs데이터 없음데이터 없음
Sanjeev Khindri
Executive Vice President of Clinical Development1.5yrs데이터 없음데이터 없음
Cheryl Lassen
Senior Vice President of Clinical Development1.5yrs데이터 없음데이터 없음

2.7yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: AVTE 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Timothy Noyes
CEO & Director3.3yrsUS$3.07m데이터 없음
Maha Katabi
Independent Director3.9yrsUS$230.01k0%
$ 0
Christian Schade
Independent Directorless than a year데이터 없음데이터 없음
Donald Santel
Independent Director1.5yrsUS$568.54k0%
$ 0
David Grayzel
Independent Director3.9yrsUS$225.99k0%
$ 0
Joshua Resnick
Independent Director3.9yrsUS$174.80k0%
$ 0
Mark Iwicki
Independent Director3.4yrsUS$218.30k0%
$ 0
Allison Dorval
Independent Director3yrsUS$185.80k0%
$ 0
Habib Dable
Independent Chairman of the Boardless than a yearUS$363.25k0%
$ 0

3.3yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: AVTE 의 이사회경험(평균 재직 기간 3.2 년)으로 간주됩니다.